Apeloa Pharmaceutical Co.Ltd(000739) march 18 announcement, MPP (i.e. "drug patent pool organization") recently issued an announcement authorizing Apeloa Pharmaceutical Co.Ltd(000739) and other 35 pharmaceutical enterprises to produce Pfizer's oral covid-19 therapeutic drugs.
Based on the license agreement, MPP grants Apeloa Pharmaceutical Co.Ltd(000739) a non exclusive, non transferable, non subcontracting and royalty license for the use of relevant patents and know-how in the region (i.e. 95 low-income countries / regions such as India, Pakistan and Vietnam) to produce, commercialize and related rights of nirmatrelvir API and nirmatrelvir / ritonavir patented authorized preparations Apeloa Pharmaceutical Co.Ltd(000739) will produce cooperative products in production facilities approved by SRA (strict regulatory authority) or prequalified by who (World Health Organization). The cooperative products produced by the company can be supplied to Pfizer and other MPP patent licensees as required, and the company can also purchase the required cooperative products from other MPP patent licensees.
According to the license agreement, in the low-income area (LIC) specified in the agreement, the company is not required to pay a patent license fee based on the sales of the preparation; In areas other than the low-income areas specified in the agreement, depending on the nature of the purchaser, the company will pay Pfizer a patent license fee of 5% or 10% of the annual net sales (as defined in the agreement). Until the who announces that covid-19 is no longer listed as a public health emergency of international concern (including the current month), the obligation of patent royalties will be suspended in the above areas.
Apeloa Pharmaceutical Co.Ltd(000739) specifically, MPP has the right to terminate this license in accordance with the license agreement. If the license agreement is terminated in advance, this agreement can also be converted into a direct license between Pfizer and the Licensee under the premise of the agreement.
The company said that the signing of this agreement is a normal business behavior, there is no affiliated relationship, and does not have a significant impact on the independence of its business. Up to now, the company has no orders in hand for cooperative products and has not carried out relevant production. This license has no significant impact on the company's current operating performance, and the impact on future performance cannot be predicted.
